• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lithuania Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Lithuania Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Lithuania
  • 96 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Profiles
  • GlaxoSmithKline
  • Local Companies
  • Merck & Co
  • Multinational Companies
  • Novartis
  • MORE

BMI View:

We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012, with the market expected to increase by a local currency margin of 2.5
%year-on-year (y-o-y) to reach LTL1.68bn (US$618mn) in 2012 at consumer prices. However, in US dollar terms, the market's value will shrink by 6.3%, indicating the challenges facing companies operating in the market.

Headline Expenditure Projections

- Pharmaceuticals: LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5
%in local currency terms and -6.3% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.

- Healthcare: LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.

- Medical devices: LTL679mn (US$273mn) in 2011 to LTL749mn (US$276mn) in 2012;
+10.3% in local currency terms and +0.8% in US dollar terms. Forecast slightly up from Q412 on account of new READ MORE >

Executive Summary 6

SWOT Analysis 8

Lithuania Pharmaceuticals And Healthcare Industry SWOT 8

Lithuania Political SWOT 9

Lithuania Economic SWOT 9

Lithuania Business Environment SWOT 10

Pharmaceuticals Risk/Reward Ratings 11
Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113 11

Rewards 12

Risks 12

Lithuania - Market Summary 14

Regulatory Regime 15

Regional Harmonisation 16

Pharmaceutical Advertising 17

Intellectual Property Developments 18

Pricing Regime 19

Pricing Developments 20
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 22
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 23

Reimbursement Regime 23

Reimbursement Developments 24

Industry Developments 26

Epidemiology 26
Table: Leading Causes of Death, 2002-2010 27

Communicable Diseases 27
Table: Selected Notifiable Infectious Diseases, 2004-2010 28
Table: Incidence of HIV & AIDS, 2002-2010 29

Healthcare System 29

Healthcare Provision 29
Table: Inpatient Institutions & Hospital Beds by Sector, 2000-2010 30
Table: Outpatient Facilities by Type, 2003-2010 30

Healthcare Funding 31

Healthcare Insurance 32

E-Health 32

Clinical Trials 33

Biotechnology 34

Recent Biotechnology Sector Developments 35

Medical Devices 36

Industry Forecast Scenario 37

Pharmaceutical Market Forecast 37
Table: Pharmaceutical Sales Indicators 2008-2016 38

Healthcare Market Forecast 39
Table: Healthcare Expenditure Indicators 2008-2016 40
Table: Healthcare Governmental Indicators 2008-2016 41
Table: Healthcare Private Indicators 2008-2016 41

Key Growth Factors - Macroeconomic 42
Table: Economic Activity 51

Prescription Drug Market Forecast 52
Table: Prescription Drug Sales Indicators 2008-2016 54

Patented Drug Market Forecast 55
Table: Patented Drug Market Indicators 2008-2016 56

Generic Drug Market Forecast 57
Table: Generic Drug Sales Indicators 2008-2016 58

OTC Medicine Market Forecast 59
Table: OTC Medicine Sales Indicators 2008-2016 60

Pharmaceuticals Trade Forecast 61
Table: Exports and Imports Indicators 2008-2016 62

Medical Device Market Forecast 63
Table: Medical Devices Sales Indicators 2008-2016 63

Key Risks To BMI's Forecast Scenario 64

Competitive Landscape 65

Pharmaceuticals Sector 65
Table: Members of the Association of Manufacturers of Drugs (VGA), 2011 65
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA) 66

Domestic Industry 66

Pharmaceutical Wholesale 67

Pharmaceutical Retail 68
Table: Pharmacies, 2000-2010 69

Pharmaceutical Distribution Developments 70

Company Profiles 72

Local Companies 72

Valentis 72

Sanitas (Valeant) 74

Sicor Biotech (Teva) 77

Multinational Companies 79

GlaxoSmithKline 79

Pfizer 81

Novartis 82

Merck & Co 83

Sanofi 84

Demographic Outlook 85
Table: Lithuania's Population By Age Group, 1990-2020 ('000) 86
Table: Lithuania's Population By Age Group, 1990-2020 (% of total) 87
Table: Lithuania's Key Population Ratios, 1990-2020 88
Table: Lithuania's Rural And Urban Population, 1990-2020 88

Glossary 89

BMI Methodology 91

How We Generate Our Pharmaceuticals Industry Forecasts 91

Pharmaceuticals Risk/Reward Ratings Methodology 92

Ratings Overview 92
Table: Pharmaceutical Business Environment Indicators 93

Weighting 94
Table: Weighting Of Components 94

Company Profiles
Local Companies
Valentis
Sanitas (Valeant)
Sicor Biotech (Teva)
Multinational Companies
GlaxoSmithKline
Pfizer
Novartis
Merck & Co
Sanofi

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos